Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
  • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/33—Heterocyclic compounds
  • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
  • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
  • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P13/00—Drugs for disorders of the urinary system
  • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Definitions

• the present invention relates to the use of 1- ⁇ 4- [4-aryl (or heteroaryl) -1-piperazinyl] -butyl ⁇ - 1-H-azole derivatives as well as their physiologically acceptable salts, for the manufacture of medicaments for the treatment of obsessive-compulsive disorder, sleep apnea, sexual dysfunction, Pemesis and motion sickness.
• the aryl (or heteroaryl) - piperazinyl-butyl-azole derivatives show anti-obsessive activity, preventive of sleep apnea, which facilitates sexual, anti-magnetic and anti-nausea behavior and therefore they are useful in therapy for the prevention and treatment of obsessive-compulsive disorder, sleep apnea, sexual dysfunction and nausea and vomiting, in particular induced by chemotherapy and / or cytotoxic radiotherapy (s) or movement.
• the compounds are intended for preventive or curative treatments in humans and in animals for depression, obsessive compulsive disorders, sleep apnea, sexual dysfunctions, emesis and motion sickness.
• Ar represents an aromatic radical, nitrogenous or not, chosen from differently substituted aryls, 2-pyrimidine differently substituted, and 3- (1, 2-benzisothiazole),
• Z1 represents a nitrogen atom or a substituted or unsubstituted carbon atom, which can be represented by: CR 1 ,
• Z2 represents a nitrogen atom or a substituted or unsubstituted carbon atom, which can be represented by: CR 2 ,
• Z4 represents a nitrogen atom or a substituted or unsubstituted carbon atom, which can be represented by: CR 4 ,
• R 1 , R 2 , R 3 and R 4 identical or different, which can also form part of another cycle, aromatic or not, represent a hydrogen atom, a halogen, a lower alkyl radical, a nitro radical, a hydroxy radical, an alkoxy radical, a cyano radical, a hydroxycarbonyl radical, an alkoxycarbonyl radical, an aryl or substituted aryl radical, a sulfonic radical, a sulfonamido radical, an aminocarbonyl radical, substituted or not on the amino group, an amino radical or substituted amino,
• Ar represents a differently substituted aryl, it is preferably a radical of formula
• alkyl is understood to mean, according to the invention, lower alkyls, preferably C 1 -C 6 , linear or branched, optionally unsaturated, in particular methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl, pentyl, hexyl radicals and their different isomers. This definition also applies to the alkyl residues of the alkoxy.
• halogen is meant according to the present invention preferably fluorine, chlorine, bromine or iodine.
• aryl is understood in particular according to the invention an aromatic or heteroaromatic radical, in particular chosen from the radicals phenyl, naphthyl, anthryl, phenanthryl, pyridyl, pyrimidyl, etc., preferably phenyl, optionally substituted, in particular by one or more radicals selected from halogens, lower alkyl radicals, nitro, hydroxy, alkoxy, cyano, hydroxycarbonyl, alkoxycarbonyl , aryl or substituted aryl, sulfonic, sulfonamido, aminocarbonyl, substituted or not on the amino, amino or substituted amino group.
• aromatic or heteroaromatic radical in particular chosen from the radicals phenyl, naphthyl, anthryl, phenanthryl, pyridyl, pyrimidyl, etc., preferably phenyl, optionally substituted, in particular by one or more radicals selected from halogens, lower
• the substituents of the amino group are in particular alkyl or aryl radicals.
• therapeutically acceptable salts is meant the usual salts of addition of organic or inorganic acids, such as hydrochlorides, dihydrochlorides, mesylates or tosylates.
• serotonin (5-HT) is involved in the pathophysiology of affective disorders
• pharmacological stimulation paradigms have been widely used to determine the "in vivo" dynamics of serotonin function in obsessive disorder compulsive, among others.
• mice are placed in the illuminated compartment which becomes aversive to them and causes them a state of anxiety. This causes a flight response to the dark compartment, which may be associated with obsessive compulsive behavior.
• the results obtained demonstrate that the lesopitron, at all the doses tested, delays the onset of obsessive-compulsive behavior of movement to the dark zone because the latency time clearly increases.
• Sleep apnea includes a series of disorders of different magnitudes. Sleep apnea is classified as obstructive, central or mixed, depending on the presence or absence of respiratory effort during periods when the air flow is stopped. Obstructive and mixed apneas are the most frequent. They present with obstructive sleep apnea syndrome, in which recurrent and sporadic collapse of the upper respiratory tract is observed during sleep. If the collapse is complete, there is no air flow through the nose and mouth, and breathing stops. The usual result is a partial awakening of sleep and a return to normal breathing. In many cases the patient does not remember these episodes of apnea, but he feels tired and sleepy during the day, for no apparent reason. These episodes of recurrent apnea with hypoxemia and fragmented sleep can lead to serious neurological and cardiac consequences.
• the rat electroencephalographic sleep study demonstrated that the 5 mg / kg lesopitron significantly increases the latency of sleep, at the same time as it decreases the total sleep time, that is, it increases waking time.
• lesopitron can be a respiratory stimulant with persistent effects during sleep. It is therefore indicated for the treatment of sleep apnea.
• the etiology of sexual dysfunction may include psychological factors, interpersonal and situational reasons, physical factors and, also, side effects of pharmacological agents. Since sexual dysfunction can be from a wide variety of these underlying causes, which can range from purely psychogenic to completely physical, it would be unrealistic to hope that only one treatment modality could become effective in any case. In usual clinical practice, sexual dysfunction is treated by determining the underlying causes and treating them when possible. In many cases the identification of the underlying causes of male and female sexual dysfunction is very complex, or even cannot be determined with certainty. The psychopharmacological treatment of sexual dysfunction is currently in its infancy. The use of drugs for the treatment of sexual dysfunction has had little success, which is evidenced by the absence of a widely accepted and recognized treatment for this use.
• the results obtained with the lesopitron demonstrate the activity of the product by facilitating the sexual behavior of the rats.
• the compounds of the invention have been studied as to their effects on emesis in ferrets according to a method described by Costall et al. (Neuropharmacology, 1986, 25, 9S9-961).
• Ferrets of both sexes were individually conditioned at 21 ⁇ 1 ° C and fed normally. They were then administered the compound of Example 32 or a vehicle subcutaneously as a pretreatment 15 minutes before administration of cisplatin (10 mg / kg i.v. by way of a fixed jugular cannula). The animals were observed at the start of emesis, and after, for 240 minutes. Emesis was characterized by rhythmic abdominal contractions, either associated with the expulsion of solid or liquid matter (i.e. vomiting), or not associated with the passage of material through the mouth (nausea). The number of episodes and nausea or vomiting were recorded.
• the compound of Example 32 is capable of antagonizing the emesis induced by cisplatin ( Figure 1).
• FIG. 1 The compound of Example 32 is capable of antagonizing the emesis induced by cisplatin in the ferret.
• the animals were observed for 240 minutes.
• a significant difference compared to V is indicated sP ⁇ 0.05 (Mann-Whitney U test).
• the administration dose is of course a function of the severity of the condition to be treated. It will generally be between about 5 and about 100 mg / day.
• the derivatives of the invention will, for example, be administered in the form of tablets, capsules, or else intravenously. Two specific dosage forms will be indicated below, by way of examples.
• the present invention extends to the application of these compounds as medicaments, to the pharmaceutical compositions containing them and to their use for the manufacture of medicaments intended for the treatment of obsessive-compulsive disorder, sleep apnea, sexual dysfunction, emesis and motion sickness.
• the manufacture of antiobsessive agents preventive of sleep apnea, which facilitate sexual behavior, antiemetic and anti-nausea.

Landscapes

• Health & Medical Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Chemical & Material Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Life Sciences & Earth Sciences (AREA)
• Engineering & Computer Science (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Epidemiology (AREA)
• Otolaryngology (AREA)
• Hospice & Palliative Care (AREA)
• Reproductive Health (AREA)
• Urology & Nephrology (AREA)
• Endocrinology (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Nitrogen Condensed Heterocyclic Rings (AREA)
• Pyrrole Compounds (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=9485400

Family Applications (1)

Country Status (16)

Families Citing this family (14)

Family Cites Families (2)

• 1995
  • 1995-12-12 FR FR9514690A patent/FR2742052B1/fr not_active Expired - Fee Related
• 1996
  • 1996-12-11 CN CN96192286A patent/CN1177297A/zh active Pending
  • 1996-12-11 AU AU13764/97A patent/AU716665B2/en not_active Ceased
  • 1996-12-11 PL PL96321779A patent/PL321779A1/xx unknown
  • 1996-12-11 CA CA002211161A patent/CA2211161A1/fr not_active Abandoned
  • 1996-12-11 JP JP9521756A patent/JPH11501051A/ja active Pending
  • 1996-12-11 EP EP96944029A patent/EP0808166A1/fr not_active Withdrawn
  • 1996-12-11 HU HU9800198A patent/HUP9800198A2/hu unknown
  • 1996-12-11 IL IL12146196A patent/IL121461A0/xx unknown
  • 1996-12-11 CZ CZ972551A patent/CZ255197A3/cs unknown
  • 1996-12-11 WO PCT/EP1996/005736 patent/WO1997021439A1/fr not_active Ceased
  • 1996-12-11 TR TR97/00794T patent/TR199700794T1/xx unknown
  • 1996-12-12 ZA ZA9610457A patent/ZA9610457B/xx unknown
  • 1996-12-12 AR ARP960105644A patent/AR004378A1/es unknown
  • 1996-12-12 ES ES009602700A patent/ES2134709B1/es not_active Expired - Lifetime
• 1997
  • 1997-08-04 NO NO973589A patent/NO973589L/no not_active Application Discontinuation

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events